207 related articles for article (PubMed ID: 21386629)
1. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Oberstein PE; Saif MW
JOP; 2011 Mar; 12(2):96-100. PubMed ID: 21386629
[TBL] [Abstract][Full Text] [Related]
2. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Li J; Saif MW
JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
[TBL] [Abstract][Full Text] [Related]
3. Molecular therapy of pancreatic cancer.
Plentz RR; Manns MP; Greten TF
Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
[TBL] [Abstract][Full Text] [Related]
4. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Ying JE; Zhu LM; Liu BX
World J Gastroenterol; 2012 Feb; 18(8):736-45. PubMed ID: 22371633
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Chang BW; Saif MW
JOP; 2011 Mar; 12(2):101-5. PubMed ID: 21386630
[TBL] [Abstract][Full Text] [Related]
6. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Saif MW
JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
[TBL] [Abstract][Full Text] [Related]
7. Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Makrilia N; Syrigos KN; Saif MW
JOP; 2011 Mar; 12(2):110-3. PubMed ID: 21386632
[TBL] [Abstract][Full Text] [Related]
8. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer: an update.
Kindler HL
Curr Oncol Rep; 2007 May; 9(3):170-6. PubMed ID: 17430687
[TBL] [Abstract][Full Text] [Related]
10. First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Ramfidis VS; Psyrri A; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):286-8. PubMed ID: 25076321
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
14. New directions in the management of advanced pancreatic cancer: a review.
Rocha-Lima CM
Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced pancreatic cancer.
Ducreux M; Boige V; Malka D
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in locally advanced or metastatic breast cancer.
Gradishar WJ
Expert Opin Investig Drugs; 2012 Aug; 21(8):1177-91. PubMed ID: 22616580
[TBL] [Abstract][Full Text] [Related]
17. Advancements in the management of pancreatic cancer.
Li J; Saif MW
JOP; 2009 Mar; 10(2):109-17. PubMed ID: 19287102
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Saif MW; Syrigos K; Penney R; Kaley K
Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment for advanced pancreatic cancer.
Kothari N; Saif MW; Kim R
JOP; 2013 Mar; 14(2):129-32. PubMed ID: 23474553
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Saif MW
JOP; 2011 Mar; 12(2):106-9. PubMed ID: 21386631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
